About this trial
Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients.
Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced.
Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2.
Part 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.
Eligibility criteria
Qualifiers
- Age > 18
Biopsy proven prostate malignancy
Definitive treatment is radiotherapy to the prostate alone
ECOG performance status 0-2
Disqualifiers
Hip prosthesis
Patient separation from prostate centre to skin edge > 24cm, measured on diagnostic scan-
Trial design
Treatments tested in this trial
- Adaptive radiotherapy +/- Margin Reduction
- Image guided radiotherapy
Treatment groups
Sponsors and collaborators
Royal North Shore Hospital
Lead sponsor
Northern Sydney and Central Coast Area Health Service
Collaborator